机译:EGFR-TKIS加上局部治疗的生存受益于单独的EGFR-TKIS在EGFR-突变体NSCLC患者中脱富莫氏菌属或寡次抗肝转移酶
Department of Medical OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of OncologyTongji Hospital of Tongji Medical College Huazhong University of Science and;
Department of Internal MedicineThe Affiliated Cancer Hospital of Zhengzhou University Henan Cancer;
Department of Medical OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of Medical OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of Medical OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of Lung Cancer and ImmunologyShanghai Pulmonary Hospital Tongji University School of;
Department of Lung Cancer and ImmunologyShanghai Pulmonary Hospital Tongji University School of;
Department of Radiation OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of Medical OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of Medical OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of Lung Cancer and ImmunologyShanghai Pulmonary Hospital Tongji University School of;
Department of Medical OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of Radiation OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of Medical OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of Medical OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Department of Medical OncologyShanghai Pulmonary Hospital &
Thoracic Cancer Institute Tongji;
Medicine and PathologyUniversity of Colorado Cancer Center Anschutz Medical CampusAurora CO;
lung cancer; liver metastases; local therapy; EGFR mutation;
机译:EGFR-TKIS加上局部治疗的生存受益于单独的EGFR-TKIS在EGFR-突变体NSCLC患者中脱富莫氏菌属或寡次抗肝转移酶
机译:oa07.03向EGFR TKI添加局部疗法在EGFR-突变体NSCLC PTS中表现出生存益处?寡核菌属或寡次抗争性肝转移酶
机译:一线持续性EGFR-TKI联合局部消融治疗证明了EGFR突变的NSCLC少进展性疾病患者的生存获益
机译:接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
机译:EGFR-TKIs在非小细胞肺癌治疗中的有效性:一项荟萃分析。
机译:一线持续性EGFR-TKI联合局部消融治疗证明了EGFR突变的NSCLC少进展性疾病患者的生存获益
机译:第一线持续的EGFR-TKI加上局部烧蚀治疗表明EGFR-突变体NSCLC患者的生存益处寡头植物的寡头竞争症